Dry Eye Disease

Global Dry Eye Disease Market to Reach US$11.0 Billion by 2030

The global market for Dry Eye Disease estimated at US$7.1 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Cyclosporine, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 11.4% CAGR

The Dry Eye Disease market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Dry Eye Disease Market – Key Trends & Drivers Summarized

What Is Fueling the Surge in Dry Eye Disease Cases Worldwide?
Dry Eye Disease (DED), medically referred to as keratoconjunctivitis sicca, is witnessing a significant global rise in prevalence due to multiple converging lifestyle, demographic, and environmental factors. This chronic ocular condition is caused by either inadequate tear production or excessive evaporation, resulting in inflammation, ocular surface damage, and persistent discomfort. Populations over the age of 50 are particularly susceptible, making aging one of the most critical contributors to the growing incidence of DED. However, younger demographics are not exempt, especially given the ubiquity of digital screens. Extended screen exposure significantly reduces blink rate and tear film stability, leading to tear evaporation and dry eye symptoms.

Urbanization and pollution are also contributing to this surge. Particulate matter, low humidity environments, and exposure to air conditioning are proven aggravators of ocular dryness. In addition, the widespread use of contact lenses, refractive surgeries like LASIK, and systemic medications such as antihistamines and antidepressants are known to exacerbate or trigger dry eye conditions. The disease affects daily tasks such as reading, driving, or prolonged visual focus, reducing quality of life and productivity. With awareness rising among both patients and healthcare providers, the rate of diagnosis is increasing, intensifying the demand for effective and accessible therapeutic solutions.

Which Innovations Are Transforming Dry Eye Disease Management?
The treatment landscape for Dry Eye Disease is undergoing rapid transformation, driven by advances in both diagnostics and therapeutic interventions. Diagnostic techniques have evolved far beyond traditional Schirmer tests, with clinicians now utilizing tear osmolarity testing, non-invasive tear break-up time analysis, and meibography to assess meibomian gland dysfunction, a leading cause of evaporative dry eye. These innovations enable precise subtyping of the disease, allowing clinicians to adopt a more targeted approach to therapy. Digital imaging tools and point-of-care analyzers are making diagnostics more accurate, faster, and accessible in both hospital and outpatient settings.

Pharmacological advancements have also redefined treatment protocols. Anti-inflammatory eye drops such as cyclosporine A and lifitegrast have emerged as frontline agents in managing chronic dry eye associated with inflammation. These drugs offer more sustained relief than artificial tears, which, although still widely used, only provide temporary symptomatic relief. Further innovation is seen in the rise of sustained-release drug delivery systems—such as drug-eluting punctal plugs and inserts—which improve therapeutic adherence and patient outcomes. Additionally, non-drug therapies like intense pulsed light (IPL) treatment, thermal pulsation devices, and in-office gland expression procedures are helping restore ocular surface health in patients with moderate to severe disease.

How Are Diverse Sectors Addressing the Challenges of Dry Eye Disease?
The rising burden of Dry Eye Disease is prompting multifaceted responses across healthcare systems, pharmaceutical companies, and even corporate employers. In the healthcare setting, early diagnosis and personalized management strategies are being emphasized. Ophthalmologists and optometrists are incorporating comprehensive ocular surface evaluations into routine checkups, recognizing the long-term implications of untreated DED. The integration of digital health platforms is also expanding access to care, with teleophthalmology services providing remote assessments, especially in underserved and rural regions. These platforms are helping monitor disease progression, reinforce medication adherence, and educate patients on environmental and behavioral modifications.

Pharmaceutical companies are aggressively investing in the development of novel compounds, combination therapies, and biologics tailored for specific subtypes of dry eye. There is a notable shift from one-size-fits-all solutions to therapies based on individual disease etiology, such as aqueous-deficient versus evaporative dry eye. At the same time, industry collaborations between biotech firms and academic research institutions are accelerating discovery pipelines through the use of ocular surface biomarkers, artificial intelligence, and big data analytics. In the corporate sector, awareness of the impact of DED on employee well-being and productivity has led to workplace interventions, such as screen time management, improved ergonomics, and indoor air quality enhancements. These cross-sector initiatives reflect a growing recognition of dry eye as not just a medical condition, but a broader public health and quality-of-life issue.

What Is Driving Market Growth and Strategic Investment in Dry Eye Disease Solutions?
The growth in the dry eye disease market is driven by several factors related to technological innovation, rising prevalence, and evolving treatment paradigms. One of the primary drivers is the global demographic shift toward an aging population, which corresponds with increased susceptibility to tear dysfunction and ocular surface damage. Equally influential is the surge in digital device usage across all age groups, as prolonged screen exposure continues to undermine blink frequency and tear film integrity, especially in urban and professional environments. These behavioral shifts are expanding the DED patient pool far beyond traditional risk categories.

On the technological front, sustained progress in drug delivery systems and diagnostics is accelerating treatment adoption and improving patient outcomes. The regulatory landscape is also becoming more conducive, with expedited approval pathways for novel ophthalmic drugs encouraging innovation and investment. In parallel, there is increasing awareness and screening activity driven by public health campaigns, eye health initiatives, and improved insurance coverage for specialty eye care. As dry eye gains recognition as a chronic and often progressive disease, healthcare stakeholders are allocating greater resources to research, product development, and patient education. These factors are collectively propelling the global dry eye disease market forward, setting the stage for sustained growth and diversification in both prescription and non-prescription segments over the next decade.

SCOPE OF STUDY:

The report analyzes the Dry Eye Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs, Other Product Types); Formulation Type (Liquid, Gel, Ointment, Other Formulation Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• AbbVie Inc.
• Akorn Operating Company LLC
• Alcon Inc.
• Aldeyra Therapeutics, Inc.
• Allergan plc (AbbVie)
• Bausch + Lomb Incorporated
• Horus Pharma
• Johnson & Johnson
• Mitotech S.A.
• Nicox S.A.
• Novaliq GmbH
• Novartis AG
• OASIS Medical
• OKYO Pharma Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Rohto Pharmaceutical Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
• Schwind eye-tech-solutions GmbH
• Sentiss Pharma Pvt. Ltd.
• Surface Ophthalmics, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.